XORTX Therapeutics Inc.

XRTX Nasdaq SEC CIK 1729214
Follow XORTX Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: fiscal 2021 CAD · IFRS
Net income −CAD 1.7M −28.6% vs prior year
EPS, diluted -
Operating cash flow −CAD 6.1M −732.3% vs prior year
Net income by fiscal year
−CAD 629.6K
−CAD 1.3M
−CAD 1.7M
FY19 FY20 FY21

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income4 fiscal years
−CAD 2M−CAD 1.5M−CAD 1M−CAD 500KCAD 0FY18FY19FY20FY21
Show the numbers
YearNet income
FY21−CAD 1.7M
FY20−CAD 1.3M
FY19−CAD 629.6K
FY18-